(Total Views: 778)
Posted On: 09/27/2024 2:38:57 PM
Post# of 148870
Cyder tries again -
My reply:
What you are missing is that .057 is not statistically significant so Cytodyn could not say "appears to have better anti-fibrotic activity" with that direct comparison p value. However p = .01 vs. p = .057 certainly is. Cytodyn has been very careful in how they state things due to past experiences.
Quote:
lol, don;t forget to post your apology.
Leronlimab monotherapy (700 mg) demonstrated statistically significant fibrosis reversal compared to an isotype IgG4 control arm (p<0.01);
what does THAT mean? let's see:
LERIONLIMAB the first thing - then "COMPARED TO" blah blah - then a pvalue.
onee thing - COMPARED TO another thing. and then a pvalue.
is that leronloimab's pvalue? OF COURSE IT IS.
ok let's try again
Leronlimab monotherapy (700 mg) appears to have better anti-fibrotic activity compared to Resmetirom (p=0.057).
what does THAT mean? let's see:
LERIONLIMAB the first thing - then "COMPARED TO" blah blah - then a pvalue.
onee thing - COMPARED TO another thing. and then a pvalue.
is that leronloimab's pvalue? OF COURSE IT IS.
how do we know? because EVERY pvalue ever presented is presented that way.
ONE THING..... COMPARED TO... ANOTHER THING...
parentheses pvalue close parentheses
lol dude, are you seriously trying that hard to fool yourself?
post the truth, and the apology.
My reply:
What you are missing is that .057 is not statistically significant so Cytodyn could not say "appears to have better anti-fibrotic activity" with that direct comparison p value. However p = .01 vs. p = .057 certainly is. Cytodyn has been very careful in how they state things due to past experiences.
(17)
(0)Scroll down for more posts ▼
